PGC-1α integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1205-1210

  Cao, Dedong ^a   Zhou, Hao ^a   Zhao, Jikai ^a   Jin, Lu ^a   Yu, Wen ^a   Yan, Han ^a   Hu, Yu ^a   Guo, Tao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

GLUT 4; Multiple myeloma; PGC 1 ; VEGF

Indexed keywords

ESTROGEN RELATED RECEPTOR ALPHA; GLUCOSE; GLUCOSE TRANSPORTER 4; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SMALL INTERFERING RNA; VASCULOTROPIN;

ARTICLE; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENDOTHELIUM CELL; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896701810     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2974     Document Type: Article

References (35)

1. Munshi NC: Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program: 297, 2008.
2. Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M and Vacca A: Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res 1: 76-89, 2011.
3. McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST and Shanmugam M: Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 119: 4686-4697, 2012.
4. Stocks T, Rapp K, Bjorge T, et al: Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6: e1000201, 2009.
5. Vacca A, Ribatti D, Roccaro AM, Frigeri A and Dammacco F: Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 28: 543-550, 2001. (Pubitemid 33134413)
6. Giatromanolaki A, Bai M, Margaritis D, et al: Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res 30: 2831-2836, 2010.
7. Sun CY, Hu Y, Huang J, et al: Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol 31: 121-128, 2010.
8. Puigserver P, Wu Z, Park CW, Graves R, Wright M and Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839, 1998. (Pubitemid 28155321)
9. Handschin C and Spiegelman BM: Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735, 2006. (Pubitemid 44936056)
10. Puigserver P and Spiegelman BM: Peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90, 2003. (Pubitemid 36223280)
11. Finck BN and Kelly DP: PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622, 2006. (Pubitemid 43326866)
12. Arany Z, Foo SY, Ma Y, et al: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 451: 1008-1012, 2008. (Pubitemid 351301733)
13. Lu J, Zhang K, Chen S and Wen W: Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression. Carcinogenesis 30: 636-644, 2009.
14. Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D and Caers J: Biological aspects of angiogenesis in multiple myeloma. Int J Hematol 94: 505-518, 2011.
15. Nikhil C and Kenneth C (eds): Advances in Biology and Therapy of Multiple Myeloma. Volume 1: Basic Science. Springer, New York, NY, 2012.
16. Adekola K, Rosen ST and Shanmugam M: Glucose transporters in cancer metabolism. Curr Opin Oncol 24: 650-654, 2012.
17. Ak I and Gulbas Z: F-18 FDG uptake of bone marrow on PET/CT scan: its correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Ann Hematol 90: 81-87, 2011.
18. Bartel TB, Haessler J, Brown TL, et al: F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114: 2068-2076, 2009.
19. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28: 3746-3753, 2010.
20. Podar K and Anderson KC: Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 11: 1005-1024, 2011.
21. Klimcakova E, Chenard V, McGuirk S, et al: PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. Cancer Res 72: 1538-1546, 2012.
22. Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004. (Pubitemid 39469126)
23. 18F-FDG PET identifies high-risk myeloma. J Nucl Med 43: 1457-1463, 2002.
24. Zhang K, Lu J, Mori T, et al: Baicalin increases VEGF expression and angiogenesis by activating the ERRα/PGC-1α pathway. Cardiovasc Res 89: 426-435, 2011.
25. Bredella MA, Steinbach L, Caputo G, Segall G and Hawkins R: Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 184: 1199-1204, 2005. (Pubitemid 43821897)
26. Gendron MC, Schrantz N, Metivier D, et al: Oxidation of pyridine nucleotides during Fas- and ceramide-induced apoptosis in Jurkat cells: correlation with changes in mitochondria, glutathione depletion, intracellular acidification and caspase 3 activation. Biochem J 353: 357-367, 2001. (Pubitemid 32096946)
27. Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786, 2006. (Pubitemid 44187625)
28. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418, 2001. (Pubitemid 32524647)
29. DeBerardinis RJ, Mancuso A, Daikhin E, et al: Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350, 2007.
30. Zhao Y, Altman BJ, Coloff JL, et al: Glycogen synthase kinase 3α and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 27: 4328-4339, 2007. (Pubitemid 46906557)
31. Danial NN, Gramm CF, Scorrano L, et al: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956, 2003. (Pubitemid 37051687)
32. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB: Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23: 7315-7328, 2003. (Pubitemid 37211011)
33. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004. (Pubitemid 39472955)
34. Plas DR and Thompson CB: Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 13: 75-78, 2002.
35. Chang CY and McDonnell DP: Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. Clin Cancer Res 18: 6089-6095, 2012.